1-[(diphenylmethyl)aminocarbonyl]-4-(diphenylmethyl) piperazine | 381248-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(diphenylmethyl)aminocarbonyl]-4-(diphenylmethyl) piperazine
• 英文别名: 4-benzhydryl-piperazine-1-carboxylic acid benzhydryl amide；N,4-dibenzhydrylpiperazine-1-carboxamide
• CAS: 381248-72-2
• 化学式: C₃₁H₃₁N₃O
• 分子量: 461.607
• InChiKey: PPVBMJIAJXVQFX-UHFFFAOYSA-N

物化性质

• 沸点：
  653.3±55.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二苯甲基哌嗪 、 异氰酸二苯甲酯 在 氮气 作用下， 以 二氯甲烷 为溶剂， 以gives the desired product in 80% yield的产率得到1-[(diphenylmethyl)aminocarbonyl]-4-(diphenylmethyl) piperazine
  参考文献：
  名称：

  Urea derivatives as calcium channel blockers

  摘要：

  含有吡啶或哌嗪环并进一步取代的尿素衍生物对于改善由不需要的钙离子通道活性所特征的病症是有效的。

  公开号：

  US20060063775A1

文献信息

• Urea derivatives as calcium channel blockers
  申请人：Pajouhesh Hassan

  公开号：US20060063775A1

  公开（公告）日：2006-03-23

  Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.

  含有哌啶或哌嗪环及其进一步取代的尿素衍生物，在改善由不良钙离子通道活性所表征的状况方面效果显著。
• Urea derivative useful as an anti-cancer agent and process for preparing same
  申请人：Chaconne Nsi Co., Ltd.

  公开号：US20020019389A1

  公开（公告）日：2002-02-14

  The present invention relates to a novel urea derivative represented by the following formula (I), which is useful as an anti-cancer agent: 1 its pharmaceutically acceptable acid addition salt or stereoisomer, in which X, Y, B and Het have the meaning as defined in the specification, and to a process for preparing the compound of formula (I) and an anti-cancer composition comprising the compound of formula (I) as an active ingredient.

  本发明涉及一种新颖的尿素衍生物，其化学式如下（I），可用作抗癌剂：其药学上可接受的酸盐或立体异构体，其中X、Y、B和Het的含义如规范中所定义，并且涉及制备化合物的公式（I）以及包含公式（I）化合物作为活性成分的抗癌组合物的方法。
• METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS
  申请人：Snutch Terrance P.

  公开号：US20090312346A1

  公开（公告）日：2009-12-17

  A method of increasing the bioavailability of a compound of formula 1 by orally administering to a patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, with food:

  通过将化合物1的化合物或其药学上可接受的盐与食物一起口服给患者的方法，来增加化合物1的生物利用度：
• UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Pajouhesh Hassan

  公开号：US20080207633A1

  公开（公告）日：2008-08-28

  Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.

  含有哌啶或哌嗪环且进一步置换的尿素衍生物对于改善由于不必要的钙离子通道活性所表现出的情况是有效的。
• Scaffold-based design and synthesis of potent N-type calcium channel blockers
  作者：Gerald W. Zamponi、Zhong-Ping Feng、Lingyun Zhang、Hossein Pajouhesh、Yanbing Ding、Francesco Belardetti、Hassan Pajouhesh、David Dolphin、Lester A. Mitscher、Terrance P. Snutch

  DOI：10.1016/j.bmcl.2009.09.008

  日期：2009.11

  The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. (C) 2009 Elsevier Ltd. All rights reserved.